Q32 Bio (QTTB) revenue and earnings history
Q32 Bio reported revenue of $53.7M for fiscal 2025 (year ended Dec 31, 2025), and net income of $29.8M.
Over 7 years, from fiscal 2018 to fiscal 2025, revenue grew at a compound rate of +46.6% a year.
Revenue and net income, 9 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $53.7M | $16.9M | $29.8M | −$33.5M | $0 | −$33.5M | $5.25M | — | — | $48.3M | — | 10-K |
| 2024ended Dec 31, 2024 | $0 |
The latest quarter, insider trades and fund moves: Q32 Bio (QTTB) on OQRO.
Common questions
What was Q32 Bio's revenue in fiscal 2025?
$53.7M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 10, 2026.
How fast has Q32 Bio's revenue grown?
From $3.68M in fiscal 2018 to $53.7M in fiscal 2025: a compound annual growth rate of +46.6% over 7 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Q32 Bio been profitable?
It reported a net loss in 8 of the years shown (2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024). The highest net income was $29.8M in fiscal 2025.
Where these figures come from
The SEC’s companyfacts data: every figure Q32 Bio tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
